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Abstract: 
 
Objective: In ICU patients, abnormal liver tests are common. Markers of cholestasis are associated with 
adverse outcome. Research has focused on the possibility that mild hyperbilirubinemia, instead of indicating 
inadvertent cholestasis, may be adaptive and beneficial. These new insights are reviewed and integrated in 
the state-of-the-art knowledge on hepato-biliary alterations during sepsis and other critical illnesses.  
Data Sources: Relevant publications were searched in Medline with search terms bile, bile acids, 
cholestasis, critical illness, intensive care, sepsis, alone or in combination.  
Data synthesis: Studies have shown that bilirubin, but also bile acids, the main active constitutes of bile, 
are increased in plasma of patients with critical illnesses. In particular the conjugated fractions of bilirubin 
and bile acids are high, indicating that during critical illness, the liver is capable of converting these 
molecules to less toxic forms. In human liver biopsies of prolonged critically ill patients, expression of bile 
acid excretion pumps towards the bile canaliculi was lower, while alternative transporters towards the 
systemic circulation were upregulated. Remarkably, in the presence of increased circulating bile acids, 
expression of enzymes controlling synthesis of bile acids was not suppressed. This suggested loss of 
feedback inhibition of bile acids synthesis, possibly explained by the observed cytoplasmic retention of the 
nuclear FXR/RXR heterodimer. As macronutrient restriction during acute critical illness, an intervention that 
improved outcome, was found to further increase plasma bilirubin while reducing other markers of 
cholestasis, a potentially protective role of hyperbilirubinemia was suggested.  
Conclusion: The increase in circulating levels of conjugated bile acids and bilirubin in response to acute 
sepsis/critical illnesses may not necessarily point to cholestasis as a pathophysiological entity. Instead it 
may be the result of an adaptively altered bile acid production and transport back towards the systemic 
circulation. How these changes could be beneficial for survival should be further investigated.  
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Introduction 
The liver plays a central role in the systemic response to sepsis and other critical illnesses by 
releasing acute-phase proteins, cytokines and coagulants, and by facilitating clearance of pathogenic 
organisms and toxins [1]. However, alterations in biochemical liver function tests are commonly observed 
in critically ill patients, and interpreted as signs of hepato-biliary dysfunction and cholestasis [2-4]. Two 
pathophysiological conditions are typically distinguished based on laboratory parameters and clinical 
presentation: “hypoxic hepatitis” and “cholestatic liver dysfunction” [5]. Both conditions are associated with 
increased morbidity, mortality and a longer hospital length of stay [2, 6-8]. 
Hypoxic or ischemic hepatitis is a well-recognized condition hallmarked by diffuse hepatocellular 
necrosis provoked by acute cellular hypoxia because of insufficient arterial blood supply of the liver. The 
laboratory findings reflect the underlying pathogenesis, as a steep increase of plasma alanine transaminase 
(ALAT) and aspartate transaminase (ASAT) and up to 20-times the upper limit of normality indicates 
hepatocytic damage and release of intracellular enzymes [3]. Approximately 5-10% of the ICU patients fulfill 
the diagnostic criteria for hypoxic hepatitis at ICU admission [3, 9]. Mortality of patients diagnosed with 
hypoxic hepatitis reflects and therefore relates to the severity of the underlying condition [3]. Acute cardiac 
failure can cause a mixed derangement of all liver parameters (alkaline phosphatase (ALP), gamma 
glutamyl transpeptidase (GGT), ALAT, ASAT and bilirubin). The most important determinants for 
abnormalities in liver parameters in heart failure are high central venous pressure and reduced hepatic 
perfusion. Comparable to hypoxic hepatitis, prognostic value was related to the extent of the underlying 
condition [10]. 
Cholestatic liver dysfunction (CLD) is traditionally defined as impaired bile formation and flow, 
caused by extrahepatic obstruction of the bile duct or by an inability of the hepatocyte to secrete bile into 
the bile duct (intrahepatic cholestasis). Obstructive cholestasis due to acute mechanical blockage of the 
canalicular system or by inflammation-driven narrowing of the bile ducts can be easily and reliably 
diagnosed by ultrasonography, but is seldom the cause of what is referred to as “CLD” during critical illness 
[11, 12]. In contrast, what is labeled CLD in critically ill patients is most often the result of non-obstructive 
intrahepatic alterations that may lead to accumulation of bilirubin and bile acids in the liver. In contrast with 
hypoxic hepatitis, clear diagnostic criteria for this type of CLD during critical illness are lacking. In fact, the 
4 
 
criterion most often used in clinical practice is a serum total bilirubin greater than 2 or 3 mg/dl [13].  Besides 
the use of bilirubin as a marker, increased ALP and GGT are also used to indicate CLD, with used thresholds 
around 2-3 times the upper limit of normality. Up to 20% of ICU patients develop CLD according to these 
diagnostic criteria, of which the majority fulfills them already upon admission to the ICU [2, 4, 9]. Risk factors 
are sepsis with gram negative bacteria, but also major surgery, trauma with systemic inflammation response 
syndrome (SIRS) and other severe shock states [7, 14]. The occurrence of CLD during critical illness is also 
associated with the use of parenteral nutrition, antibiotics and other medications [15, 16].  
Although increased amounts of bile acids and bilirubin within the hepatocyte are presumed to be 
the culprit in inducing the clinical presentation of CLD, the underlying molecular and biochemical pathways 
are poorly characterized. Furthermore, whether hyperbilirubinemia during critical illness truly reflects 
cholestasis is not clear. Overt hyperbilirubinemia in the prolonged phase of critical illness may not be the 
same as a mild increase of circulating bilirubin, which is almost always observed during the acute phase of 
critical illnesses. In addition, many other factors can affect bilirubin such as hemolysis, blood transfusion 
and (viral) infections of the liver. Furthermore, proof of causality in the link between hyperbilirubinemia and 
worse outcomes is still lacking. Hyperbilirubinemia might also be merely a biochemical epiphenomenon, 
indicative of severe hepatobiliary dysfunction, or it could reflect a transient and adaptive response during 
critical illness. Better insights into the pathophysiological and molecular aspects of hepatobiliary alterations 
during critical illness are clearly needed. In addition, the role of bile acids in the CLD that is present during 
critical illness has largely been overlooked, despite their known pivotal role in bile formation and in the 
metabolism of cholesterol and lipids [17].  
The aim of this article is to review recent novel insights in the hepatobiliary transport and regulation 
of bilirubin and bile acids during critical illness and integrate these in the state of the art knowledge on this 
topic.  
 
The normal hepatobiliary transport 
The formation and excretion of bile is one of the key functions of the liver (Figure 1A).  Bile consists 
mainly of bile acids, that are known for their role in dietary lipid absorption in the small intestine [18]. Bile 
synthesis and secretion is also important for the removal of excess cholesterol, bilirubin, and excretion of 
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endogenous toxic compounds and xenobiotics. In the hepatocyte, primary bile acids are synthesized from 
their precursor molecule cholesterol by an extensive enzymatic cascade [18]. The rate limiting enzyme 
CYP7A1 is regulated by multiple mechanisms and serves as the primary target in the negative feedback 
inhibition controlling the synthesis of bile acids [18]. The two primary bile acids produced by the liver are 
cholic acid (CA) and chenodeoxycholic acid (CDCA). The majority of CA and CDCA are conjugated in the 
liver with glycine or taurine, which enhances their physiological function. After secretion in the intestinal 
lumen, primary bile acids are transformed by the bacterial flora of the gut into the secondary bile acids 
deoxycholic acid (DCA) and litocholic acid (LCA) and their respective conjugates (Figure 2). Secondary bile 
acids are absorbed in the intestinal lumen and transported to the liver, where they are reconverted to their 
primary form. 
 
Bile acid uptake and export transporters 
The hepatocyte is a strongly polarized cell type that features specific hepatobiliary transporters for 
the uptake and excretion of biliary constituents from the blood compartment into the bile compartment (Table 
1). Cell polarity is maintained through the presence of tight junctions and the cytoskeleton to create 
distinctive basolateral and apical cell membranes. Hepatic excretion of bile acids to the bile canaliculi is the 
rate limiting factor in bile salt dependent bile flow. The apical excretion is mainly mediated by the bile salt 
export pump (BSEP) [19]. Other apical but less specific bile acid transporters are the multidrug resistance 
protein (MDR) and multidrug resistance associated protein (MRP) family. MRP2 transports amphipathic 
conjugates (including bilirubin and bile acids), MDR1 and MDR3 excrete cytotoxic agents and xenobiotics 
(among which bile acids) [20]. Excreted bile acids are delivered to the small intestine through the bile ducts. 
The majority of these bile acids are efficiently reabsorbed in the enterocytes of the small intestine and 
transported through the portal circulation back to the liver, which is known as the enterohepatic cycle. 
Reuptake of bile acids from the blood into the hepatocyte is mainly mediated by the high affinity Na+ 
dependent bile acid transporter (NTCP) and the less specific organic anion transporting polypeptide (OATP). 
Aside from these influx systems, the basolateral membrane expresses the export transporters MRP3 and 
MRP4 [21, 22]. In normal conditions, only low levels of these export transporters are expressed at the 
basolateral membrane of hepatocytes through which a small fraction of bile acids in the portal circulation 
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escapes the hepatic extraction, and can re-enter the systemic circulation. From the systemic circulation, bile 
acids can also be directly excreted by the kidneys, although highly efficient reabsorption minimizes urinary 
excretion, even under cholestatic conditions [23].  
 
Regulation of bile acid homeostasis 
The homeostasis of bile acids is regulated through a group of nuclear hormone receptors, a family 
of intracellular, ligand dependent transcription factors [24]. In the nuclear receptor family, the farnesoid X 
receptor (FXR) has the highest affinity for bile acids. FXR activation leads to reduced expression of 
basolateral uptake transporters and stimulation of apical export transporters of bile acids, and has therefore 
a self-regulating role by interfering with the intracellular concentration of its ligand. Binding of bile acids to 
FXR in hepatocytes also induces the expression of a small heterodimer partner (SHP) that inhibits the key 
enzyme CYP7A1 in bile synthesis [25, 26]. Furthermore, SHP inhibits target genes of other nuclear 
receptors including the expression of bile acid transporters [27]. Other nuclear receptors with bile acid affinity 
are the vitamin D receptor (VDR), pregnane X receptor (PXR) and constitutive androstane receptor (CAR) 
[28, 29]. All bile acid-sensing nuclear receptors operate in a heterodimer form with the obligatory partner 
retinoid X receptor alpha (RXRα) (Figure 1A).  
Because of the highly efficient reuptake system in the enterohepatic organs only a small amount of 
bile acids is present in the systemic circulation, although circulatory bile acids can increase 4 to 6 times after 
a meal [30]. The ingestion of meals regulates daily variation in serum bile acids concentration, although 
regulation by the circadian clock might also play a role [31]. These factors result in a diurnal rhythm that 
allows bile acids to serve as systemic metabolic signaling molecules to peripheral tissues. Indeed, 
circulatory bile acids have an additional important metabolic regulatory role besides their function in dietary 
lipid absorption and bile acid homeostasis [32-36]. These peripheral effects are mainly mediated by the 
nuclear receptor FXR and via the G-coupled TGR-5 receptor [32, 34, 36].  
 
Hepatobiliary transport during critical illness 
Pathophysiological manifestations of the critical illness associated CLD 
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Histologically, cholestatic abnormalities in the liver during critical illness are characterized by 
hepatocellular bilirubinostasis, sinusoidal dilatation, an increased number of infiltrating cells in the sinusoid 
and Kupffer cell hyperplasia [37]. The increase in cell size from Kupffer cells in combination with infiltrating 
polymorphonuclear cells, eosinocytes and platelets induces aggregate formation which can lead to 
obstruction of the sinusoidal lumen [37]. The resulting hypoperfusion of the sinusoid can be suspected by 
the presence of a dilated Disse’s space. The centrolobular region is typically most affected, as it is a 
metabolically active region that hosts the p450 enzymes, while it has only little oxygen available [38]. In 
severe illness, apoptosis and necrosis of liver parenchyma can be observed [37, 39]. Besides hepatocellular 
bilirubinostasis, signs of bilirubinostasis can also be found in the canalicular and ductular bile ducts [40]. 
This phenomenon is driven by loss in contractile activity of actin and myosin microfilaments, which play a 
key role in the transport of bile acids trough the canalicular route [38, 41]. The impairment in polymerization 
and depolymerization of microfilaments results in the loss of canalicular membrane contraction and leads 
to bile ducts paralysis, distension and bile secretory failure [37]. Development of such canalicular changes 
have been observed in septic shock patients and after long term treatment in the ICU and are associated 
with severe morbidity [42, 43]. These histological findings can be accompanied by radiological abnormalities 
and biliary sludge, although ultrasonographic changes are also observed in patients without suspected 
biliary abnormalities [11, 12]. However, as explained above, presence of CLD during critical illness is mostly 
suspected clinically by elevated plasma bilirubin, as liver biopsies that would be required to confirm true 
cholestasis are hardly ever available for this indication given the invasiveness of this procedure.  
 
Bile acid transport during critical illness 
The majority of the current insights in the alterations that occur in the hepatocellular bile acid 
transport during critical illness are based on acute animal models challenged with pro-inflammatory agents 
such as LPS or cytokines. However, also limited but quite valuable data are available from studies of human 
patients (Figure 1B).  
In endotoxemic and septic animal studies and in critically ill humans, gene expression and protein 
levels of the basolateral uptake pump NTCP are markedly downregulated, likely due to suppression of 
essential transcription factors by pro-inflammatory cytokines [44-46]. The OATP uptake transporters are 
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also downregulated by inflammation-induced mechanisms [45-47]. In rat endotoxemia and in LPS-treated 
human liver slices, a suppressed expression of the export pumps BSEP and MRP2 protein levels has been 
observed [48, 49]. Also in biopsies harvested immediately postmortem from critically ill patients, BSEP 
protein expression was dramatically reduced, whereas upregulated MRP2 gene expression was reported 
[45]. MDR1 and MDR3, involved in the export of toxic compounds to the bile canaliculi are upregulated 
during critical illness in humans [45]. The most prominent changes observed in both animal and human 
studies are the increase in the basolateral export pumps MRP3 and MRP4 at both the transcriptional and 
translational level [45, 48, 50] (Figure 3). Normally MRP3 and MRP4 are expressed at very low levels in 
hepatocytes, but upregulation is observed during inflammation and longstanding cholestasis, presumably 
shifting transport of bile acids back to the blood compartment. In human liver biopsies, MRP3 correlated 
strongly with histological bilirubinostasis and serum bilirubin and conjugated bile acids, suggesting that 
MRP3 upregulation may be a compensatory reaction to cholestasis [51].  
Retrospective analysis of pre-agonal serum from ICU non-survivors demonstrated elevated bile 
acid levels (11-fold) and elevated bilirubin (8-fold) levels [45]. Predominantly the conjugated forms of both 
bilirubin and bile acids were increased, which implies that the liver was still capable of converting these toxic 
compounds to their less toxic conjugated forms [45]. Despite the increased circulating levels of bile acids, 
hepatic protein levels of CYP7A1, which is the rate limiting enzyme for bile acid synthesis, was not 
suppressed in liver biopsies from these patients [45]. The absence of a suppressed CYP71A1 protein 
expression in the face of quite elevated plasma bile acids suggests that the normal feedback inhibition is 
suppressed during critical illness, with ongoing synthesis despite increased bile acid availability.  
The observed alterations in plasma bile acid levels and in the expression of hepato-biliary 
transporters in liver biopsies harvested immediately postmortem from human patients coincided with a 
remarkable decrease in the hepatocytic nuclear amount of the nuclear bile acid receptors FXR, PXR, CAR 
and their obligatory partner RXR  [45] (Figure 1B). Again this is compatible with an at least partial loss of 
bile acid sensing and feedback regulation of de novo bile acids production that occurs during the course of 
critical illness. In vitro and in vivo models suggest that nuclear export of these receptors is regulated through 
c-Jun N-terminal kinases which can be activated by inflammatory mediators [52].  
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Together, these findings suggest that the so-called “cholestasis”, with high plasma bilirubin and bile 
acids, in acute critical illness is brought about by alterations in the hepatobiliary transport system. Critical 
illness induces an immediate increase in conjugated bile acids and bilirubin in the circulation, apparently 
through a reversal of the normal bile acid transport, back into the blood. Furthermore, the hepatocyte of a 
critically ill patient appears to switch off the nuclear bile acid sensors. Whether this is a maladaptive or an 
adaptive response cannot be concluded from these data and should be further investigated.  
 
Pathologies/Interventions that affect CLD during critical illness 
Sepsis 
 Sepsis and extrahepatic bacterial infection with inflammation are often accompanied by a rise in 
cholestatic markers [53]. A prospective analysis showed that sepsis is the second leading cause of 
cholestasis in clinically jaundiced patients [54]. Cholestasis in sepsis is linked predominantly to infections 
by Gram-negative bacteria, especially with an intra-abdominal focus. In addition, pneumonia, pyelonephritis 
and endocarditis have been linked to ICU jaundice [14]. Animal models of sepsis confirmed that endotoxin 
and inflammatory cytokines can alter the expression of the transporters for bile acids and bilirubin. 
Translocation of bacteria and endotoxin due to failure of the gut barrier might further enhance the altered 
hepatobiliary transport. Furthermore, reduced bile flow in the intestine has been suggested to augment this 
translocation, which might play a role in sustaining endotoxemia during the course of systemic inflammation 
[55]. However, similar alterations in bile acid transporter expression have been observed in an animal model 
of severe burn injury [51]. Furthermore, also non-septic critically ill patients display elevated plasma bilirubin 
levels, often already upon admission to the ICU [45, 56]. These observations suggest a more general 
underlying trigger as the main cause of the altered bilirubin and bile acid transport (Figure 4). 
 
Parenteral nutrition 
Parenteral nutrition is often administered during the course of critical illness when patients cannot 
be fed enough macronutrients via the enteral route. However, lack of enteral feeding and the administration 
of lipids through parenteral nutrition are thought to contribute to the development of CLD during critical 
illness [57]. The impact of parenteral nutrition on the development of CLD during critical illness has been 
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assessed in a 3rd degree burn rabbit model [51]. In this model, markers of liver damage were significantly 
lower in the group of animals that were fasted as compared with those that received parental nutrition [51]. 
Also, in this animal model, fasting during the course of illness induced a shift from unconjugated to 
conjugated circulating bile acids, in a higher hepatic expression of the efflux transporter MRP3 and a lower 
expression of FXR [51].  Markers of hepato-biliary function were also studied in a large clinical randomized 
controlled study of 4640 patients on the effect of early versus late initiation of parenteral nutrition on the 
outcome of critical illness (EPaNIC) [58]. This study showed that delaying the initiation of parental nutrition 
to beyond the first week of critical illness was associated with fewer infections, less organ failure and 
significantly shorter duration of intensive care dependency and hospitals stay [58, 59]. Biochemical markers 
of hepatocytic damage (maximum levels ALT) and of cholestasis (GGT, ALP) were lower in the group that 
did not get parenteral nutrition during the first week. In contrast, plasma bilirubin was significantly higher in 
this group throughout the 7-day intervention window, and became equal to the group receiving parenteral 
nutrition as soon as parenteral nutrition was started also in the fasting group beyond that first week [60]. 
These findings clearly suggest that hyperbilirubinemia during critical illness not necessarily reflects true 
cholestasis. Given that those higher levels of bilirubin occurred in the group that experienced fewer 
complications and had better outcomes may also suggest an adaptive nature of the stress-induced rise in 
plasma bilirubin.  
 
Hyperglycemia 
 In two randomized controlled trials assessing the impact of blood glucose control on outcome of 
critical illness in adults, in a context of early parenteral nutrition, an effect of preventing hyperglycemia on 
hepatobiliary function has been shown. Lowering blood glucose levels with insulin reduced biliary sludge 
and cholestasis in prolonged critical illness. [9, 60-62]. 
 
Drug induced cholestasis 
With use of animal models it was also demonstrated that critical illness induces hepatic 
biotransformation and suppressed excretory function, which may account for the accumulation of not only 
bile acids and bilirubin, but also for exogenous xenobiotics [63, 64].  Drugs administered as part of the 
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intensive care of ICU patients could therefore reflect a toxic threat to the hepatocytes. Accumulation of drugs 
can directly cause hepatocyte damage, but also exert toxic accumulation of bile acids, bilirubin and toxins 
by inhibition of canalicular transporters and interference with nuclear receptors [65]. Canalicular transporters 
form the rate limiting step in clearance of lipophilic drugs and their metabolites by excretion along with bile. 
Drugs with biliary excretion are contribute in the development of jaundice [66]. However, the majority of 
drugs are standard care in daily ICU practice. Cholestatic dysfunction is described for basically all 
antibiotics. Anesthetics and sedatives form another major group of commonly used drugs in the ICU 
associated with cholestasis. Currently, except for some specific toxins, there are no commonly used 
strategies available to eliminate this burden, besides discontinuation of potentially harmful drugs. Although 
extracorporal liver support systems are known to reduce circulating bile acids, bilirubin and toxins, this is 
not routine practice in ICU medicine.   
 
Critical illness induced CLD: beneficial or maladaptive?  
One could speculate that the reversal of the hepato-biliary transport back to the blood could reflect 
an escape to cope with the inability of the hepatocyte to excrete bile acids against the concentration gradient 
into the bile ducts, which would thus be a protective mechanism of the hepatocyte to prevent toxicity of 
intracellular bile acids and bilirubin. Alternatively, ongoing bile acid production with a reversal of normal flow 
into the circulation can reflect an adaptive process in order to increase systemic effects of circulating bile 
acids and bilirubin. Indeed, bilirubin may attenuate organ damage by improving endothelial function and 
protecting against oxidative stress and high glucose levels [67-71]. Knock-out mice lacking heme 
oxygenase, which is the rate limiting factor in bilirubin production, have shown to have a higher mortality 
and more organ damage after induction of LPS than wild type mice [71]. In an animal model of LPS induced 
sepsis, bilirubin treated rats had significantly lower expression of markers of hepatocyte damage and 
showed improved survival [70]. The protective role of bilirubin showed to be, at least in part, mediated by 
inhibiting hepatic iNOS expression [70]. Another investigated mechanism in which bilirubin reduced cellular 
damage is redox cycling. Bilirubin can react with reactive oxygen species (ROS), which neutralizes the 
toxicity and oxidizes bilirubin to biliverdin. Biliverdin can be converted back to bilirubin through biliverdin 
reductase. By repeating this cycle, the antioxidative and cytoprotective effect of small amounts of bilirubin 
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is greatly amplified [69]. In addition, bile acids have shown to reduce cortisol metabolizing enzymes in rats 
[72]. An association between bile acids and cortisol was later also described in critically ill patients, 
suggesting that an increased availability of bile acids during critical illness may explain the reduced 
breakdown of cortisol, hereby contributing to elevated plasma cortisol concentrations and higher cortisol 
availability in vital organs and tissues, thus playing a key role in the stress response [73]. Potentially, a 
metabolic effect of bile acids on energy metabolism could play a protective role to reduce the hypermetabolic 
response of acute critical illness. Indeed, bile acids can regulate glucose, cholesterol, triglyceride and 
energy homeostasis and are promising novel drug targets in the treatment for metabolic diseases [33-36]. 
Activation of bile acid signaling pathways increases energy expenditure and prevents development of insulin 
resistance [74]. In addition, bile acids have shown to increase insulin secretion by inducing the production 
of glucagon-like peptide-1 [75]. Mildly elevated bilirubin and/or bile acids could theoretically also have a 
protective role in advanced liver disease. However, in these patients hyperbilirubinemia is present in a much 
longer timeframe than observed during critical illness and the severity appears to reflect the extent of the 
underlying pathogenesis [76]. 
However, the alterations observed in the hepatocytes during critical illness not only increase levels 
of bilirubin and bile acids. Drugs and other xenobiotics that are administered in daily ICU practice can easily 
accumulate due to decreased bile excretion. Reduced bile flow in the intestine has also been shown to exert 
translocation of the gut microbiome and could play a role in sustained release of endotoxin in the systemic 
circulation [55]. A prolonged lack of bile acids in the intestine can cause malabsorption of lipids and vitamins. 
In addition, sustained molecular changes in bile acid signaling pathways can be harmful. Evidence suggests 
that bile acids and FXR signaling regulate cell growth and inhibit tumor genesis. Animals lacking FXR or its 
downstream target SHP develop hepatocellular carcinoma [77, 78]. Furthermore, high levels of conjugated 
bilirubin in mice induce erythrocyte cell death which could contribute to anemia [79]. 
 
Besides supportive care and interventions to prevent liver damage, no treatment options are 
currently available for CLD. Reducing the load of inflammatory signaling molecules to the liver 
microenvironment, in order to decrease the need for an adaptive response may be desirable. The latter can 
be achieved by reducing risk factors that provoke CLD, such as prevention of hyperglycemia and avoiding 
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the administration of parenteral nutrition during acute critical illness [9, 60]. Opioids have been suggested 
to attenuate the inflammatory response and sequential liver injury, but this is still being investigated in vitro 
and in vivo, and thus clinical evidence is currently lacking [80, 81]. Ursodeoxycholic acid (UDCA) is used in 
various cholestatic liver diseases and improves clinical and/or laboratory parameters [82]. There is however 
currently no evidence to support the use of UDCA in critically ill patients.  
 
The possible protective role of mild hyperbilirubinemia during critical illness questions the relevance 
of assessing liver dysfunction in ICU patients exclusively via laboratory parameters and of prognosticating 
via organ dysfunction scores that include bilirubin (table 2) [13, 83, 84].  
 
Conclusion 
In conclusion, alterations of biochemical cholestasis markers during the course of critical illness 
reflect a multifactorial process, involving hepatic biotransformation and altered transporter expression. The 
current evidence is insufficient to conclude on whether these alterations reflect true cholestasis or only 
indicate a biochemical epiphenomenon. Whether the hepato-biliary alterations must be interpreted as 
maladaptive or adaptive changes also needs to be further elucidated. Bilirubin might therefore not be the 
ideal marker to asses liver dysfunction as it is currently used in organ assessment scores. Only an 
interventional study, in which circulating bilirubin levels can be actively and directly manipulated, can answer 
the questions whether the mild hyperbilirubinemia that is uniformly present during acute critical illness is a 
beneficial response that protects against adverse outcomes. Also, in order to explore possible specific 
therapeutic targets, the molecular pathways involved in the pathophysiology of the different aspects of 
critical illness-induced CLD needs to be further elucidated. The novel insight that alterations in nuclear 
receptors may play a key role during critical illness opens perspectives for future research and to ultimately 
develop better targeted strategies to improve outcome.  
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Table 1: 
Protein 
name Localization Uptake/export Function 
Expression during 
critical illness [45, 51] 
NTCP Basolateral Uptake 
Primary uptake transporter of bile acids from portal 
circulation  Downregulated 
OATP Basolateral Uptake 
Multispecific uptake transporter of organic anions 
(including bilirubin) and bile acids from portal circulation Downregulated 
BSEP Apical Export 
Primary export transporter of bile acids to the canalicular 
system Downregulated 
MRP2 Apical Export 
Multispecific export transporter of organic anions 
(including bilirubin) and bile acids from portal circulation Upregulated 
MRP3 Basolateral Export 
Multispecific export of organic anions to systemic 
circulation Upregulated 
MRP4 Basolateral Export 
Multispecific export of organic anions to systemic 
circulation Upregulated 
MDR1 Apical Export 
Excretion of organic cations, xenobiotics and cytotoxic 
agents Upregulated 
MDR3 Apical Export 
Excretion of organic cations, xenobiotics and cytotoxic 
agents Upregulated 
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Table 2: 
Scoring 
system 
(range) 
Collection of 
data 
Selection of variables and 
their weights 
Used feature for liver 
evaluation 
Classification 
cut-offs 
Weight 
Apache IV Admission Multiple logistic regression Bilirubin (mg/dl) < 1.9 0 
(0 - 286)       2.0 – 2.9 5 
        3.0 – 4.9 6 
        5.0 – 7.9 8 
        > 8.0 16 
SAPS-II Admission Multiple logistic regression Bilirubin (mg/dl) < 4.0 0 
(0 - 163)       4.0 – 5.9 4 
        > 6.0 9 
SOFA Daily (worst in 24 
hours) 
Expert opinion Bilirubin (mg/dl) <1.2 0 
(0 - 24)     1.2 – 1.9 1 
        2.0 – 5.9 2 
    6.0 – 11.9 3 
        > 12.0 4 
MODS Daily (morning) Literature review and multiple 
logistic regression 
Bilirubin (mg/dl) < 1.2 0 
(0 - 24)     1.2 – 3.5 1 
        3.5 – 7.0 2 
        7.0 – 14.0 3 
        >14.0 4 
21 
 
Figure 1: 
 
Figure 1: Hepato-biliary transport system in (A) normal conditions and (B) during critical illness. 
During the course of critical illness the specific uptake transporter NTCP and less specific OATP 
transporters are downregulated. Also the specific export pump BSEP is downregulated. MRP3 and MRP4, 
pumps mediating alternative export to the systemic circulation are upregulated. Simultaneously, nuclear 
receptors are no longer located in the nucleus of the hepatocyte and unable to bind to their respective 
response elements. Abbreviations: NTCP: Na+-taurocholate co-transporting polypeptide. OATP: Organic 
anion transporting polypeptide. BSEP: Bile salt export pump. MRP: Multidrug resistance-associated protein. 
FXR: Farnesoid X receptor. RXR: Retinoid X receptor alpha. PXR: Pregnane X receptor. VDR: Vitamin D 
receptor 
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Figure 2: 
 
Figure 2: Bile acid differentiation. The primary bile acids cholic acid (CA) and Chenodeoxycholic Acid 
(CDCA) are formed by the hepatocyte from their precursor molecule cholesterol. In the liver, these primary 
bile acids are conjugated with glycine or taurine, which improves their physiological function and decreases 
their toxicity. In the intestinal lumen, these primary bile acids are converted by the gut microbiome to 
secondary bile acids, which are efficiently reabsorbed and recycled in the enterohepatic cycle.   
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Figure 3: 
 
Figure 3: Representative liver sections for MRP3 and MDR3. Left panel: Control patients. Right panel: 
ICU patients. (A) Normal basolateral MRP3 staining showing clear centrolobular and midzonal activity (left 
panel). Markedly up-regulated panlobular honeycomb MRP3 staining pattern (right panel). (B) Normal 
pattern of a fine canalicular linear MDR3 staining (left panel). Strong double-stranded pattern of MDR3 
staining around multiple dilated canaliculi (right panel). Abbreviations: MRP, multidrug resistance-
associated protein; MDR, multidrug resistance protein; CV, centrolobular vene; PT, portal tract. 
Reproduced with permission from Vanwijngaerden, Y.-M., Wauters, J., Langouche, L., Vander Perre, S., 
Liddle, C., Coulter, S., Vanderborght, S., Roskams, T., Wilmer, A., Van den Berghe, G. and Mesotten, D. 
(2011), Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and 
nuclear receptor expression. Hepatology, 54: 1741–1752 
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Figure 4: 
Figure 4: Course and features of critical illness associated cholestasis. The orange line represents 
plasma levels of bilirubin and bile acids during the course of critical illness. A steep rise in the acute phase 
of critical illness coincides with the burst of inflammatory cytokines as a consequence of sepsis, trauma of 
severe burn injury. Additional factors that can affect markers of cholestasis are persistent or new septis 
episodes, drugs, parenteral nutrition and hyperglycemia. In the recovery phase, bilirubin levels and bile acid 
are assumed to decrease to baseline levels again. Abbreviations: BA, bile acids; TPN, total parenteral 
nutrition; ICU, intensive care unit 
 
